Searchable abstracts of presentations at key conferences in endocrinology

ea0007p94 | Endocrine tumours and neoplasia | BES2004

Somatostatin and VEGF expression within the larynx

Bedford K , MacDonald A , Condon L , Stafford N , Atkin S

IntroductionSomatostatin has antiproliferative, anti-angiogenic and pro-apoptotic actions through 5 G-protein receptors (Sstr). In view of the anti-angiogenic effects of Sstrs their relationship to the distribution of vascular endothelial growth factor (VEGF) was undertaken in non-malignant Reinke's Oedema of the larynx and squamous cell carcinoma of the larynx.MethodsSix Reinke's oedema (non malignant) and 1...

ea0005p75 | Cytokines and Growth Factors | BES2003

Overexpression of somatostatin receptors 1 and 5, and VEGF and its receptors FLK and FLT in laryngeal carcinoma: Potential targets for anti-tumoral therapy?

Condon L , Rogers M , Macdonald A , Stafford N , Atkin S

IntroductionThe prognosis in head and neck cancer has remained unchanged over the last 20 years (overall 5 year survival 50-60 percent), and is adversely affected by tumour angiogenesis. The effects of the anti-proliferative and anti-angiogenic peptide somatostatin (SST) are mediated through a family 5 receptors (SSTRs 1-5), whilst the angiogenic cytokine vascular endothelial growth factor (VEGF) acts predominantly via 2 receptors: FLK and FLT. The objective of this study ...